[HTML][HTML] Combination ATR and PARP Inhibitor (CAPRI): A phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian …
PD Shah, SL Wethington, C Pagan, N Latif, J Tanyi… - Gynecologic …, 2021 - Elsevier
Objective Platinum-resistant, high-grade serous ovarian cancer (HGSOC) has limited
treatment options. Preclinical data suggest that poly (ADP-ribose) polymerase inhibitors …
treatment options. Preclinical data suggest that poly (ADP-ribose) polymerase inhibitors …
The first 5 years of uterus transplant in the US: a report from the United States uterus transplant consortium
L Johannesson, E Richards, V Reddy, J Walter… - JAMA …, 2022 - jamanetwork.com
Importance Uterus transplant is a viable surgical treatment for women affected by absolute
uterine-factor infertility, which affects 1 in 500 women. Objective To review transplant and …
uterine-factor infertility, which affects 1 in 500 women. Objective To review transplant and …
C ombination A TR (ceralasertib) and PARP (olaparib) I nhibitor (CAPRI) Trial in Acquired PARP Inhibitor–Resistant Homologous Recombination–Deficient Ovarian …
SL Wethington, PD Shah, L Martin, JL Tanyi… - Clinical Cancer …, 2023 - AACR
Purpose: Addition of ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) to
PARP inhibitors (PARPi) overcomes PARPi resistance in high-grade serous ovarian cancer …
PARP inhibitors (PARPi) overcomes PARPi resistance in high-grade serous ovarian cancer …
Incidence of venous thromboembolism by type of gynecologic malignancy and surgical modality in the National Surgical Quality Improvement Program
Background Women with gynecologic cancer are at higher risk of venous thromboembolism
(VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The …
(VTE) due to malignancy, pelvic surgery, increased age, and frequently comorbidities. The …
Impact of Medicaid expansion on women with gynecologic cancer: a difference-in-difference analysis
Background Women with gynecologic cancer face socioeconomic disparities in care that
affect survival outcomes. The Affordable Care Act offered states the option to expand …
affect survival outcomes. The Affordable Care Act offered states the option to expand …
Brain metastasis in gestational trophoblastic neoplasia: an update.
NL Neubauer, N Latif, K Kalakota… - The Journal of …, 2012 - europepmc.org
Objective To update the treatment of brain metastases in gestational trophoblastic neoplasia
(GTN) at the Brewer Trophoblastic Disease Center, comparing treatment and outcomes from …
(GTN) at the Brewer Trophoblastic Disease Center, comparing treatment and outcomes from …
[18F]FluorThanatrace ([18F]FTT) PET Imaging of PARP-Inhibitor Drug-Target Engagement as a Biomarker of Response in Ovarian Cancer, a Pilot Study
AR Pantel, SB Gitto, M Makvandi, H Kim… - Clinical Cancer …, 2023 - AACR
Purpose: PARP inhibitors have become the standard-of-care treatment for homologous
recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not …
recombination deficient (HRD) high-grade serous ovarian cancer (HGSOC). However, not …
Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.
SL Wethington, PD Shah, LP Martin, JL Tanyi, NA Latif… - 2021 - ascopubs.org
5516 Background: Following multiple blockbuster studies demonstrating long-term
progression free and overall survival benefits with poly (ADP-ribose) polymerase inhibitors …
progression free and overall survival benefits with poly (ADP-ribose) polymerase inhibitors …
Oncologic outcomes of minimally invasive versus open radical hysterectomy for early stage cervical carcinoma and tumor size< 2 cm: a systematic review and meta …
Objective To investigate the oncologic outcomes of patients with early-stage cervical
carcinoma and tumor size< 2 cm who underwent open or minimally invasive radical …
carcinoma and tumor size< 2 cm who underwent open or minimally invasive radical …
Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma
D Nasioudis, AF Haggerty, RL Giuntoli II, RA Burger… - Gynecologic …, 2019 - Elsevier
Objective Primary mucinous ovarian carcinoma (MOC) is a rare histologic subtype of ovarian
cancer. The benefit of adjuvant chemotherapy for patients with MOC is unclear. Patients and …
cancer. The benefit of adjuvant chemotherapy for patients with MOC is unclear. Patients and …